Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Vaylen vs AgelessRx

Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 83 edge.

Higher Match Score

Vaylen

#5 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen
VS

AgelessRx

#16 · Grade B

Budget-conscious patients who also value a longevity-medicine framing and some brand access.

Visit AgelessRx

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
88
Speed to Start
88
80
Formulary Match
94
84
Support Level
86
84
Flexibility
86
86
Transparency
88
78

Price, coverage & formulary

DetailVaylenAgelessRx
Semaglutide$179/mo$139/mo
Tirzepatide$239/moNot disclosed
CoverageAll 50 statesNot disclosed
Brand-name accessYesYes
Oral / sublingualYesInjectable only
Match Score87 · B+83 · B
Winner: Vaylen

Vaylen edges out AgelessRx, 87 to 83 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.

AgelessRx is still a fair pick if its strengths line up with yours — best for: Budget-conscious patients who also value a longevity-medicine framing and some brand access.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Vaylen reviewFull AgelessRx review

More head-to-heads

Or browse alternatives to Vaylen and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.